Search
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Research
FluBubs: Safety and immunogenicity of Early Quadrivalent Influenza VaccineChristopher Tobias Blyth Kollmann MBBS (Hons) DCH FRACP FRCPA PhD PhD, M.D., SFUW Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;
Research
Linkage of the Australian Childhood Immunisation Register (ACIR) and state-based registers to evaluate and inform Australia’s immunisation programChristopher Hannah Tom Blyth Moore Snelling MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Centre
Research
Moort Vax Waangkiny: Understanding reasons for routine vaccine uptake among Aboriginal children aged <5 years in Perth (Boorloo) metroAboriginal children aged younger than 5 years in Perth (Boorloo) have lower vaccine uptake compared to non-Aboriginal children.
Research
Paediatric Active Enhanced Diseases Surveillance (PAEDS)PAEDS monitors for key vaccine preventable conditions and severe side effects from vaccine in 5 paediatric hospitals in Australia.
Research
Impact for DCDMelissa Gail Matt Jenny Andrew Videos Licari Alvares Cooper Downs Whitehouse Watch and listen to Andrew PhD PhD BCA Marketing, BSc Statistics and
News & Events
Launch of National Autism GuidelineResearchers from The Kids Research Institute Australia, working with the Autism CRC, have led the development of the National Guideline for the Assessment and Diagnosis of Autism Spectrum Disorder in Australia which was launched today.
Research
Intellectual DisabilityAbout 2 per cent of children are estimated to have an intellectual disability. The cause of the condition is unknown in at least 50 per cent of cases.
